• Par Pharmaceutical, Inc. et al. v. Eagle Pharmaceuticals Inc. (D. Del.). Representing Par Pharmaceutical, Inc. in Hatch-Waxman case filed against multiple generic companies involving Par's VASOSTRICT® product. Case is ongoing.
    • Endo Pharmaceuticals Inc. vs. Teva Pharmaceuticals USA, Inc., et al. (D. Del.). Trial counsel representing Endo Pharmaceuticals in numerous Hatch-Waxman patent infringement case regarding Endo's OPANA® ER controlled-release oxymorphone product against seven generic pharmaceutical manufacturers. Obtained verdict of infringement and validity, which were affirmed by the Federal Circuit.
    • SCA Hygiene Products v. First Quality Baby Products (S. Ct.), Member of small Dechert team representing SCA that persuaded the U.S. Supreme Court in a 7-1 decision to overturn 100 years of precedent and bar the defense of laches to claims for patent damages.
    • Endo Pharmaceuticals v. Teva, et al. (S.D.N.Y.). Trial counsel for Endo Pharmaceuticals in Hatch-Waxman Act case filed against a dozen ANDA filers involving Endo's OPANA® ER product. Following a five-week trial, the court ruled in Endo's favor, finding its patents valid and infringed. The Federal Circuit affirmed.
    • Endo Pharmaceuticals Inc., et al. v. Watson Laboratories, Inc., Mylan, Noven and TWi (D. Del.). Trial counsel for Endo Pharmaceuticals Inc. and Teikoku Seiyaku Co. Ltd. in ANDA litigation against Paragraph IV filers, involving the Lidoderm® patch. Following a six-day bench trial against Watson, the first-filer, that case was settled. Other related cases settled before trial.
    • Endo Pharmaceuticals v. Impax, Actavis, Barr, Sandoz, Watson and Roxane (D.N.J.). Represented Endo Pharmaceuticals Inc. in Hatch-Waxman Act ANDA cases filed against six generic companies involving Endo’s branded oxymorphone extended release tablet (OPANA® ER), two of which went to trial. Case settled during trial.
    • Stiefel Laboratories v. Perrigo (D. Del.) Represented GlaxoSmithKline entities in an ANDA case relating to ROGAINE® Foam. Case settled. 
    • In re Paxil Antitrust Litigation; BCBS of Minnesota v. GlaxoSmithKline (E.D. Pa.). Represented a Fortune 100 research-based pharmaceutical company in these companion monopolization and attempted monopolization class action and opt out cases based on allegations of sham patent litigation and unlawful intellectual property strategies. All of the cases were settled.
    • Pfizer, Inc. Represented Pfizer, a pharmaceutical company, in patent matters relating to Pfizer’s animal health business, one of the largest in the world.
    • U.S. ex rel. Piacentile v. SmithKline Beecham Corporation d/b/a GlaxoSmithKline. Represented SmithKline Beecham Corporation d/b/a GlaxoSmithKline in this FCA case, where after GSK filed its motion to dismiss, the plaintiff voluntarily agreed to dismiss his complaint with prejudice.  
    • Confidential Client. Represented a pharmaceutical manufacturer in a government investigation of its sales and marketing practices, including issues relating to off-label promotion and alleged violations of the Anti-Kickback Statute. 
    • Confidential Client. Represented a number of individuals in connection with a government investigation of off-label marketing practices by a pharmaceutical manufacturer.
    • Managing IP Life Sciences Forum — Virtual (June 16-17, 2021)
      Speaker, “Litigation Case Law Developments – Federal Circuit and District Court”
    • ChIPs (Chiefs of Intellectual Property), Philadelphia Chapter
    • Philadelphia Intellectual Property Law Association